CRISPR THERAPEUTICS AG
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.2M | $1.5M | $864.0K | $889.0K | $892.0K | $865.0K | $35.7M | $602.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $67.2M | $68.6M | $83.5M | $58.9M | $69.9M | $72.5M | $71.7M | $82.2M |
| SG&A Expense | $17.6M | $17.2M | $18.4M | $16.9M | $18.9M | $19.3M | $18.1M | $17.4M |
| Operating Income | $-117.3M | $-130.2M | $-154.8M | $-132.1M | $-229.3M | $-148.4M | $-64.6M | $-110.1M |
| Operating Margin | -1,151.8% | -8,933.3% | -17,912.5% | -14,854.8% | -25,709.0% | -17,158.8% | -181.0% | -18,294.0% |
| Interest Expense | $3.3M | $553.0K | — | — | $0 | $0 | — | — |
| Pretax Income | $-90.2M | $-122.1M | $-130.0M | $-105.8M | $-207.3M | $-134.9M | $-36.6M | $-85.1M |
| Income Tax Expense | $960.0K | $839.0K | $614.0K | $619.0K | $1.3M | $1.1M | $700.0K | $876.0K |
| Net Income | $-91.2M | $-122.9M | $-130.6M | $-106.4M | $-208.5M | $-136.0M | $-37.3M | $-85.9M |
| Net Margin | -895.3% | -8,431.5% | -15,117.2% | -11,973.1% | -23,379.9% | -15,722.1% | -104.5% | -14,276.1% |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 |
| Shares Outstanding (Basic) | 96.5M | 96.1M | 89.9M | 91.3M | 87.1M | 85.9M | 84.4M | 85.2M |
| Shares Outstanding (Diluted) | 96.5M | 96.1M | 89.9M | 91.3M | 87.1M | 85.9M | 84.4M | 85.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |